GlassScriptPhysician profile
John W Boggess
NPI 1699731935
$8,898.20
in general payments reported to CMS, 2019-2025
58 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $956 · 2021: $1,296 · 2022: $1,291 · 2023: $1,416 · 2024: $1,384 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,231.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,621.39 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $817.07 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $526.52 | 2019-2024 | Xifaxan, Relistor, Trulance |
| Amgen INC. | $504.77 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $435.41 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $363.53 | 2021-2025 | Rexulti |
| Amarin Pharma, INC. | $328.90 | 2019-2022 | |
| Exact Sciences Corporation | $302.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $292.81 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $281.85 | 2019-2025 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $281.49 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $263.75 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $219.81 | 2023-2025 | Keveyis, Recorlev |
| Allergan, INC. | $214.13 | 2019-2020 | |
| Novo Nordisk INC | $190.48 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Boggess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.